Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies
Open Access
- 21 December 2006
- journal article
- research article
- Published by Elsevier BV in Annals of Oncology
- Vol. 18 (3), 546-550
- https://doi.org/10.1093/annonc/mdl413
Abstract
Background: The purpose of this study was to assess the efficacy and tolerability of i.v. dexrazoxane [Savene™ (EU), Totect™ (US)] as acute antidote in biopsy-verified anthracycline extravasation. Patients and methods: Two prospective, open-label, single-arm, multicentre studies in patients with anthracycline extravasation were carried out. Patients with fluorescence-positive tissue biopsies were treated with a 3-day schedule of i.v. dexrazoxane (1000, 1000, and 500 mg/m2) starting no later than 6 h after the incident. Patients were assessed for efficacy (the possible need for surgical resection) and toxicity during the treatment period and regularly for the next 3 months. Results: In 53 of 54 (98.2%) patients assessable for efficacy, the treatment prevented surgery-requiring necrosis. One patient (1.8%) required surgical debridement. Thirty-eight patients (71%) were able to continue their scheduled chemotherapy without postponement. Twenty-two patients (41%) experienced hospitalisation due to the extravasation. Mild pain (10 patients; 19%) and mild sensory disturbances (nine patients; 17%) were the most frequent sequelae. Haematologic toxicity was common as expected from the fact that the extravasation occurred during a chemotherapy course. Other toxic effects were transient elevation of alanine aminotransferases, nausea, and local pain at the dexrazoxane injection site. Conclusion: Dexrazoxane proved to be an effective and well-tolerated acute treatment with only one out of 54 assessable patients requiring surgical resection (1.8%).Keywords
This publication has 17 references indexed in Scilit:
- Treatment of anthracycline extravasation in mice with dexrazoxane with or without DMSO and hydrocortisoneCancer Chemotherapy and Pharmacology, 2005
- Dexrazoxane for anthracycline extravasation and GM-CSF for skin ulceration and wound healingThe Lancet Oncology, 2004
- Extravasation: a dreaded complication of chemotherapyAnnals Of Oncology, 2003
- DEXRAZOXANE - A PROMISING ANTIDOTE IN THE TREATMENT OF ACCIDENTAL EXTRAVASATION OF ANTHRACYCLINESScandinavian Journal of Plastic and Reconstructive Surgery and Hand Surgery, 2003
- Retrospective Study of the Management of Chemotherapeutic Extravasation InjuryAnnals of Plastic Surgery, 2002
- A New Conservative Approach to Extravasation of Anthracyclines with Dimethylsulfoxide and DexrazoxaneActa Oncologica, 2001
- Dexrazoxane is a potent and specific inhibitor of anthracycline induced subcutaneous lesions in miceAnnals of Oncology, 2001
- Adriamycin extravasation: Surgical treatment and possible prevention of skin and soft‐tissue injuriesJournal of Surgical Oncology, 1983
- Phase I evaluation of ICRF-187 (NSC-169780) in patients with advanced malignancyCancer, 1981
- Clinical course and management of accidental adriamycin extravasationCancer, 1977